Sign Out
Reproduction studies in animals (mice and rats) with orally and parenterally administered Moxiclav have shown no teratogenic effects. In a single study in women with pre-term, premature rupture of the foetal membrane (pPROM), it was reported that prophylactic treatment with Moxiclav may be associated with an increased risk of necrotizing enterocolitis in neonates. As with all medicines, use should be avoided in pregnancy, especially during the first trimester, unless considered essential by the physician.
Moxiclav may be administered during the period of lactation.
With the exception of the risk of sensitization, associated with the excretion of trace quantities in breast milk, there are no detrimental effects for the infant.
